logo-loader
viewKazera Global PLC

Kazera Global gains as it commissions MSA Group to carry out exploration programme in Namibia

The AIM-listed firm said the exploration programme was designed to test and define total mineralisation across the area of Namibia Tantalite Investment Mine

kazera mine
Kazera said the new drilling programme will predominantly focus on tantalum and lithium resources across the licence

Kazera Global PLC (LON:KZG) shares gained 10% on Thursday after the group confirmed that it has commissioned the MSA Group (MSA), a leading provider of exploration, mineral resources and reserve estimation, to carry out the targeted exploration programme.

The AIM-listed firm said the exploration programme was designed to test and define total mineralisation across the area of Namibia Tantalite Investment Mine (NTI), which forms the strategic focus of African Tantalum Limited (Aftan).

READ: Kazera to up drilling in Namibia to gauge long-term potential of tantalum mine

Kazera said the new drilling programme will predominantly focus on tantalum and lithium resources across the licence.

The company said MSA has mobilised to the site to begin the programme and will provide updates on JORC results as each specific ore body is drilled, tested and analysed. 

In late afternoon trading, Kazera shares were 10.5% higher at 2.10p.

 -- Adds share price --

Quick facts: Kazera Global PLC

Price: 0.5 GBX

AIM:KZG
Market: AIM
Market Cap: £1.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen CEO details expansion of key coronavirus trial to patients in home

Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the...

12 minutes ago

2 min read